1307220-12-7

Basic information

• Product Name: 4-[3-(4-bromo-2-fluoro-phenyl)-ureido]-benzoic acid
• Synonyms: 4-[3-(4-bromo-2-fluoro-phenyl)-ureido]-benzoic acid
• CAS NO: 1307220-12-7
• Molecular Weight: 353.147
• Mol File: 1307220-12-7.mol

Chemical Properties

• CAS DataBase Reference: 4-[3-(4-bromo-2-fluoro-phenyl)-ureido]-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(4-bromo-2-fluoro-phenyl)-ureido]-benzoic acid(1307220-12-7)
• EPA Substance Registry System: 4-[3-(4-bromo-2-fluoro-phenyl)-ureido]-benzoic acid(1307220-12-7)

Safety Data

• Hazardous Substances Data: 1307220-12-7(Hazardous Substances Data)

Upstream product

• 889373-97-1 4-[3-(4-bromo-2-fluoro-phenyl)-ureido]-benzoic acid ethyl ester 

Downstream Products

• 1374203-78-7 4-(3-{2-fluoro-4-[7-(5-methyl-furan-2-yl)4-morpholin-4-yl-quinazolin-2-yl]-phenyl}ureido)dimethyl-benzamide 
• 1374203-79-8 N,N-dimethyl-4-{3-[4-(4-morpholin-4-yl-7-pyrimidin-5-yl-pyrido[3,2-d]-pyrimidin-2-yl)-phenyl]-ureido}-benzamide 
• 1374203-80-1 5-(2-(4-(3-(4-(dimethylcarbamoyl)phenyl)ureido)phenyl)-4-morpholino-quinazolin-7-yl)furan-2-carboxylic acid 
• 1374208-57-7 methyl 5-(2-(4-(3-(4-(dimethylcarbamoyl)phenyl)ureido)phenyl)-4-morpholino-quinazolin-7-yl)furan-2-carboxylate 
• 1374203-82-3 4-(3-(4-(7-(5-cyanofuran-2-yl)-4-morpholino-quinazolin-2-yl)-3-fluorophenyl)ureido)-N,N-dimethyl-benzamide 
• 1374203-83-4 4-(3-(4-(7-(5-acetylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)ureido)-2-fluoro-N,N-dimethyl-benzamide 
• 1374208-68-0 4-{3-[2-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]-ureido}-N,N-dimethyl-benzamide 
• 1374208-67-9 4-[3-(4-bromo-2-fluoro-phenyl)-ureido]-N,N-dimethyl-benzamide 

Relevant articles and documents

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.